Meiji Yasuda Asset Management Co Ltd. Acquires Shares of 9,979 United Therapeutics Corporation $UTHR

Meiji Yasuda Asset Management Co Ltd. bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, Holdings Channel reports. The firm bought 9,979 shares of the biotechnology company’s stock, valued at approximately $5,407,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in UTHR. BlackRock Inc. acquired a new stake in United Therapeutics in the 2nd quarter valued at about $2,868,735,000. Avoro Capital Advisors LLC lifted its position in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of United Therapeutics by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after purchasing an additional 295,221 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after purchasing an additional 70,829 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $513.12 on Monday. United Therapeutics Corporation has a 1 year low of $302.19 and a 1 year high of $609.35. The stock has a 50-day moving average price of $533.08 and a two-hundred day moving average price of $537.80. The stock has a market cap of $22.01 billion, a price-to-earnings ratio of 18.36, a PEG ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the previous year, the business posted $6.41 EPS. United Therapeutics’s revenue for the quarter was down 1.9% on a year-over-year basis. Sell-side analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $170,968,483.28. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,631,280.08. This represents a 15.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 442,575 shares of company stock worth $239,326,330 over the last ninety days. 8.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

UTHR has been the subject of several research reports. Royal Bank Of Canada lowered their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Morgan Stanley set a $515.00 price objective on United Therapeutics in a research report on Thursday, August 6th. Bank of America dropped their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Weiss Ratings upgraded shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Finally, JPMorgan Chase & Co. lifted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $646.00.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.